New Delhi, 29/12: Indigenous vaccine maker Biologocial E Limited’s Corbevax received the Drug Controller General of India’s (DCGI) approval to conduct trials as booster shots, sources told ANI.
Bharat Biotech’s Covaxin also sought to conduct trials for booster doses after Prime Minister Narendra Modi announced the rollout of Covid-9 booster doses from January 10.
The Subject Expert Committee (SEC) granted Biological E the permission to conduct proposed phase three trials as Covid-19 ‘booster dose’ on two conditions. The company is asked to study the administration of booster dose in two cohorts of six and nine months with age-wise stratification. Also, 50 per cent of subjects should be of high risk or comorbidity condition.